All Releases
 |
ARYx Therapeutics Presents Clinical Data for ATI-5923 at American Heart Association Scientific Sessions 2008
Nov 14, 2008
|
15.3 KB |
|
| |
NEW ORLEANS, Nov. 14 /BusinessWire/ -- ARYx Therapeutics (NASDAQ; ARYX) announced today that clinical data for ATI-5923, a novel vitamin K epoxide reductase (VKOR) inhibitor in Phase 2/3 development for the treatment of patients at risk of forming dangerous blood clots, were presented this week at the American Heart Association (AHA) Scientific Ses...
|
|
ARYx Reports Third Quarter 2008 Financial Results
Nov 12, 2008
|
18.2 KB |
|
| |
FREMONT, Calif., Nov 12, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided an update on its products for the third quarter ended September 30, 2008. An announcement of the completion of an agreement to raise $21.6 million in a private placement is contained in an accompanying press relea...
|
|
ARYx Therapeutics Inc. Announces $21.6 Million Private Placement -- New Funding Improves Strategic Position for Product Collaborations
Nov 12, 2008
|
11.2 KB |
|
| |
FREMONT, Calif., Nov 12, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it has entered into a securities purchase agreement in connection with a private placement to a group of accredited investors led by new investor New Enterprise Associates (NEA) with participation from significant existing shareholders includ...
|
|
ARYx Therapeutics Schedules Third Quarter 2008 Results and Earnings Call
Nov 5, 2008
|
9.5 KB |
|
| |
FREMONT, Calif., Nov 05, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today that a conference call to discuss third quarter 2008 results will be held on Wednesday, November 12, 2008 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 877-604-9674
Di...
|
|
ARYx Therapeutics Inc. Completes Enrollment in EmbraceAC Study -- Phase 2/3 Clinical Trial Comparing Anticoagulant ATI-5923 Against Warfarin
Nov 3, 2008
|
14.0 KB |
|
| |
FREMONT, Calif., Nov 03, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced it has completed enrollment in EmbraceAC, a Phase 2/3 double-blind clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial is to ...
|
|
ARYx to Present at the Oppenheimer & Co. 19th Annual Health Care Conference
Oct 28, 2008
|
9.3 KB |
|
| |
FREMONT, Calif., Oct 28, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the Oppenheimer & Co. 19th Annual Health Care Conference in New York, NY. A live webcast of the presentation scheduled for Tuesday, November 4 at 2:40 p.m. Eastern Time may be accessed at the ARYx website http://www.aryx.co...
|
|
ARYx Therapeutics Appoints Amgen Executive to Board of Directors
Aug 29, 2008
|
10.1 KB |
|
| |
FREMONT, Calif., Aug 29, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced the appointment of David Beier to its board of directors. Mr. Beier is a veteran of the biotechnology industry and has been instrumental in the development of United States public policy impacting biotechnology companies, having served in both the...
|
|
ARYx Therapeutics, Inc. Announces Successful Results of Chronic Constipation Clinical Trial on ATI-7505
Aug 22, 2008
|
14.3 KB |
|
| |
FREMONT, Calif., Aug 22, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced the results of a Phase 2b clinical trial testing the safety and efficacy of its prokinetic agent, ATI-7505, in patients with chronic idiopathic constipation. The clinical trial, conducted by Procter and Gamble Pharma...
|
|
ARYx Reports Second Quarter 2008 Financial Results
Aug 13, 2008
|
18.3 KB |
|
| |
FREMONT, Calif., Aug 13, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided an update on its products for the second quarter ended June 30, 2008.
"During the second quarter of 2008, we made substantial progress in advancing our clinical and corporate programs, through the initiation o...
|
|
ARYx Therapeutics Schedules Second Quarter 2008 Results and Earnings Call
Aug 6, 2008
|
9.9 KB |
|
| |
FREMONT, Calif., Aug 06, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today that a conference call to discuss second quarter 2008 results will be held on Wednesday, August 13, 2008 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 866-31...
|
|
ARYx Therapeutics, Inc. Announces Procter & Gamble Exercises Option to End Collaboration on ATI-7505
Jul 2, 2008
|
14.6 KB |
|
| |
FREMONT, Calif., Jul 02, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced that Procter & Gamble Pharmaceuticals, Inc. (P&G) has utilized a one-time thirty day cancellation option linked to the completion of a Thorough QT (TQT) study to end the collaboration agreement between the co...
|
|
ARYx Therapeutics, Inc. Announces Successful Results of QT Study on ATI-7505
Jul 2, 2008
|
15.7 KB |
|
| |
FREMONT, Calif., Jul 02, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced the results of an important cardiac safety study on its prokinetic agent, ATI-7505. The overall results of a Thorough QT (TQT) study designed to demonstrate whether electrocardiographic effects are seen at therapeuti...
|
|
ARYx Therapeutics Inc. Cancels Jefferies Healthcare Conference Presentation
Jun 23, 2008
|
10.9 KB |
|
| |
FREMONT, Calif., Jun 23, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today regretfully announced it will not be able to present at the Jefferies 2nd Annual Healthcare Conference in New York City on June 25, 2008. The company is working with its partner Procter & Gamble Pharmaceuticals (P&G) to finalize their analyses and r...
|
|
ARYx Therapeutics Inc. Commences Phase 2/3 Clinical Trial on Oral Anticoagulant Agent ATI-5923 - EmbraceAC Comparative Study Against Leading Anticoagulant Warfarin
Jun 17, 2008
|
13.6 KB |
|
| |
FREMONT, Calif., Jun 17, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced it has commenced enrollment in a Phase 2/3 clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial, named EmbraceAC, is to evalua...
|
|
ARYx Reports First Quarter 2008 Financial Results
May 13, 2008
|
18.1 KB |
|
| |
FREMONT, Calif., May 13, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided an update on its products for the first quarter ended March 31, 2008.
"The first several months of 2008 have been an exciting time for ARYx," said Dr. Paul Goddard, chairman and chief executive officer of ARYx...
|
|
ARYx Therapeutics Schedules First Quarter 2008 Results and Earnings Call and Clarifies Expiration of Lock-Up Period
Apr 30, 2008
|
12.3 KB |
|
| |
FREMONT, Calif., Apr 30, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today a conference call to discuss first quarter 2008 results will be held on Tuesday, May 13, 2008 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In: 866-356-4123
Dial In (I...
|
|
ARYx to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
Apr 25, 2008
|
10.5 KB |
|
| |
FREMONT, Calif., Apr 25, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference in Key Biscayne, Florida. A live webcast of the presentation scheduled for Friday, May 2 at 9:10 a.m. Eastern Time may be accessed at the ARYx website http://ww...
|
|
ARYx Therapeutics Enters Clinic with Novel Antipsychotic Drug for Patients with Schizophrenia
Apr 22, 2008
|
13.4 KB |
|
| |
FREMONT, Calif., Apr 22, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it has received clearance from the Food and Drug Administration (FDA) to initiate clinical testing of ATI-9242, a novel antipsychotic for the treatment of schizophrenia and other psychiatric disorders. The company has begun dosing healthy vol...
|
|
ARYx Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results
Mar 12, 2008
|
20.4 KB |
|
| |
FREMONT, Calif., Mar 12, 2008 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (Nasdaq:ARYX) today reported financial results for the fourth quarter and year ended December 31, 2007.
"2007 was a year of tremendous growth and accomplishment for ARYx," said Dr. Paul Goddard, chairman and chief executive officer of ARYx. "During this productive year, we...
|
|
ARYx Therapeutics Schedules Fourth Quarter and Year End 2007 Results and Earnings Call
Mar 6, 2008
|
9.9 KB |
|
| |
FREMONT, Calif., Mar 06, 2008 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ: ARYX), a biopharmaceutical company, announced today a conference call to discuss fourth quarter and year ended December 31, 2007 results on Wednesday, March 12, 2008 at 8:00 a.m. Pacific Time.
The dial-in information for the call is as follows:
Dial In...
|
|
|
Print page 
Email page 
Shareholder Briefcase
Printed Materials
Download Library
Glossary
RSS News Feeds
